Welcome to our dedicated page for Can-Fite BioPharma Ltd. news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. stock.
Can-Fite BioPharma Ltd. (CANF) is a clinical-stage biotechnology company whose news flow centers on the development of orally administered small-molecule drugs targeting the A3 adenosine receptor. On this page, readers can follow company announcements on clinical trial progress, regulatory designations, patent developments, financing events, and corporate actions related to its oncology, liver disease, inflammatory, and sexual dysfunction programs.
Recent news has highlighted pivotal and mid-stage clinical studies, including a Phase III trial of Namodenoson in advanced hepatocellular carcinoma, a Phase IIb trial in MASH, and a Phase IIa study in pancreatic cancer. The company has also reported compassionate use cases in advanced liver disease and cirrhosis, as well as long-term survival outcomes in liver cancer patients treated with Namodenoson. For Piclidenoson, updates include Phase III psoriasis development and protocol preparation for rare diseases such as Lowe Syndrome, along with preclinical findings in vascular dementia models.
News items also cover CF602, an A3AR allosteric modulator in development for erectile dysfunction, including patent allowances and grants in markets such as Brazil, the United States, and Europe. Can-Fite regularly reports on its intellectual property strategy, out-licensing and distribution agreements for human and veterinary indications, participation in industry conferences, and capital markets activities such as public offerings, warrant amendments, and share structure changes like reverse splits and ADS ratio adjustments.
Investors and observers can use this CANF news feed to monitor key milestones that may affect the company’s clinical pipeline, regulatory interactions, partnering discussions, and financial position over time.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) reported a net loss of $14.44 million for the year ended December 31, 2020, an increase from $12.62 million in 2019. Revenues decreased to $0.76 million, down 63% from $2.03 million. Their cash position improved to $8.26 million from $2.69 million due to $17.68 million in financing activities. Can-Fite announced a $42.7 million out-licensing deal with Ewopharma and is progressing with clinical trials for drugs targeting COVID-19, psoriasis, and liver cancer.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) announced an upcoming interview with CEO Dr. Pnina Fishman on The RedChip Money Report®, airing on March 20th at 7 p.m. ET. In the interview, Dr. Fishman will discuss significant milestones and the company’s proprietary drug pipeline targeting inflammatory, cancer, and liver diseases. Notably, Can-Fite's lead candidates include Piclidenoson and Namodenoson, both in advanced clinical studies. This interview aims to reach a large audience, potentially impacting investor interest.
Can-Fite BioPharma Ltd (NYSE American: CANF, TASE: CFBI) announced positive results from a preclinical study on its drug candidate CF602 for treating erectile dysfunction (ED) in diabetic rats. The study showed that CF602, particularly at a 500 nM dose, led to significant improvements in ED compared to placebo groups (p0.001). The market for ED therapies is projected to reach $3.2 billion by 2022, and the company sees CF602 as a valuable candidate due to its safety profile as a topical treatment. Can-Fite also has other drugs in development targeting common and severe conditions.
Can-Fite BioPharma Ltd. (NYSE American: CANF) has signed an exclusive distribution agreement with Ewopharma for its drugs Piclidenoson and Namodenoson. The agreement includes an upfront payment of $2.25 million and potential milestone payments of up to $40.45 million, along with 17.5% royalties on net sales. Piclidenoson is aimed at treating psoriasis, while Namodenoson targets liver diseases like hepatocellular carcinoma (HCC) and NASH. This partnership offers Can-Fite immediate access to Central Eastern European markets and non-dilutive funding.
Can-Fite BioPharma Ltd. (NYSE American: CANF) has commenced a Phase II COVID-19 study, enrolling the first of 40 patients. The study, randomized and double-blind, evaluates Piclidenoson combined with standard supportive care versus placebo in hospitalized patients with moderate to severe COVID-19. Efficacy assessments will occur at Day 29, focusing on clinical status and safety data. Piclidenoson is a first-in-class treatment with proven anti-inflammatory effects, also being tested in psoriasis trials. The company's lead drug is positioned in multi-billion dollar markets addressing cancer and liver diseases.
Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI) announced promising results from its Phase II study of Namodenoson for advanced liver cancer, showcasing nearly 4 years of overall survival in two patients, with notable improvements in ascites and liver function. The FDA and EMA approved the pivotal Phase III trial design, which plans to enroll 450 patients. Namodenoson holds Orphan Drug Designation and Fast Track Status in the U.S. This development marks a significant step towards a New Drug Application for hepatocellular carcinoma treatment.
Can-Fite BioPharma (NYSE American: CANF) announced the successful completion of pre-clinical studies showing that its CBD-rich T3/C15 cannabis fraction has an inhibitory effect on liver fibrosis. This condition, associated with severe liver diseases like NAFLD and HCC, involves the excessive buildup of scar tissue in the liver. The studies revealed that the therapeutic effects are mediated through the A3 adenosine receptor (A3AR). Can-Fite's drug candidate Namodenoson is progressing to pivotal Phase III trials for liver cancer and Phase IIb for NASH, with patent applications filed for cannabinoid-based therapies.
Can-Fite BioPharma (NYSE American: CANF, TASE: CFBI) has published a webinar focusing on its drug candidate Namodenoson for treating NASH, hosted by CEO Dr. Pnina Fishman and featuring KOL Dr. Stephen Harrison. Namodenoson successfully completed a Phase II study for NAFLD/NASH, and the company is preparing a Phase IIb study. Dr. Harrison emphasized the drug's potential in treating NASH, especially in high-risk patients. Can-Fite is actively pursuing regulatory pathways for accelerated approval based on its clinical results.
Can-Fite BioPharma Ltd (NYSE American: CANF, TASE: CFBI) announced the publication of a scientific paper on its drug Namodenoson for advanced hepatocellular carcinoma (HCC) with Child-Pugh B cirrhosis. Although the Phase II trial did not meet its primary endpoint, it showed significant survival benefits for patients with a CPB score of 7, with some patients remaining under treatment for over 3.5 years. The FDA and EMA have approved the protocol for a Phase III study. Namodenoson has received Orphan Drug and Fast Track Designation from the FDA.
Can-Fite BioPharma Ltd (NYSE American: CANF, TASE: CFBI) has received approval from Israel's Ministry of Health to conduct pre-clinical studies on cannabinoid fractions at nanomolar concentrations. This assessment aims to explore effects on cancer, inflammatory, and fat cells, potentially minimizing the adverse effects associated with higher concentrations. Can-Fite's research will be conducted in its labs, utilizing patent-pending formulations and assays. The medical cannabis market, projected to grow at a CAGR of 29%, positions Can-Fite strategically for advancements in this emerging field.